NYSE:BHVN (USA) Also Trade In: Germany
Biohaven Pharmaceutical Holding Co Ltd $ 65.01 1.85 (2.93%)
Warning! GuruFocus has detected 4 Severe warning signs with BHVN. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for BHVN (Biohaven Pharmaceutical Holding Co Ltd) from 2017 to Oct 01 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Biohaven Pharmaceutical Holding stock (BHVN) PE ratio as of Oct 01 2020 is 0. More Details
Biohaven Pharmaceutical Holding PE Ratio (TTM) Historical Data
View and export this data going back to 2017. Start your Free Trial
Biohaven Pharmaceutical Holding PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:ALLK NAS:BPMC NAS:BLUE NAS:AGIO NAS:ARWR NAS:CCXI NAS:HALO NAS:PTCT NAS:DCPH NAS:FGEN OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.